Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycininduced pulmonary fibrosis in rats

Clinical and Investigative Medicine

Volumn 34, Issue 6, 2011, Pages

  Tulek, Baykal ^a   Kiyan, Esen ^b   Toy, Hatice ^a   Kiyici, Aysel ^a   Narin, Cuneyt ^a   Suerdem, Mecit ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BLEOMYCIN; GAMMA INTERFERON; INTERLEUKIN 13; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET-DERIVED GROWTH FACTOR A; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; LUNG; LUNG FIBROSIS; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLEOMYCIN; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA; INTERLEUKIN-13; LUNG; MALE; PLATELET-DERIVED GROWTH FACTOR; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84858594806     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Perez A, Rogers RM, Dauber JH. The prognosis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Suppl):S19-26.
2. du Bois RM. Diffuse lung disease: a view for the future. Sarcoidosis Vasc Diffuse Lung Dis. 1997 Mar;14(1):23-30.
3. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998 Jul;31(5):335-40.
4. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology. 1999 Nov;117(5):1198-204.
5. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005 Jul;33(1):9-13.
6. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006 Apr 1;173(7):769-76.
7. Kradin RL, Sakamoto H, Jain F, Zhao LH, Hymowitz G, Preffer F. IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Exp Mol Pathol. 2004 Jun;76(3):205-11.
8. Richeldi L, Davies HR, Ferrara G, Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003(3):CD002880.
9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362-82.
10. Borzone G, Moreno R, Urrea R, Meneses M, Oyarzun M, Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001 Jun;163(7):1648-53.
11. Serrano-Mollar A, Closa D, Cortijo J, Morcillo EJ, Prats N, Gironella M, et al. P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine. Thorax. 2002 Jul;57(7):629-34.
12. Cortijo J, Cerda-Nicolas M, Serrano A, Bioque G, Estrela JM, Santangelo F, et al. Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats. Eur Respir J. 2001 Jun;17(6):1228-35.
13. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988 Apr;41(4):467-70.
14. Bhatt N, Baran CP, Allen J, Magro C, Marsh CB. Promising pharmacologic innovations in treating pulmonary fibrosis. Curr Opin Pharmacol. 2006 Jun;6(3):284-92.
15. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allogra? rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000 Jul 15;356(9225):194-202.
16. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, et al. Long-term improvement in renal function with sirolimus a?er early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation. 2003 Jul 27;76(2):364-70.
17. Buschhausen L, Kamm M, Arns W, Schulze-Lohoff E, Weber M. [Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin]. Med Klin (Munich). 2005 Mar 15;100(3):161-4.
18. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J. 2002 Jun;19(6):1124-7.
19. Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008 Apr;44(4):507-11, 14-7.
20. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994 Nov 10;331(19):1286-92.
21. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007 Oct;132(4):1311-21.
22. Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol. 2008;40(3):484-95.
23. de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect. 2006 Mar;19(2):85-90.
24. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004 Aug;15(4):255-73.
25. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005 Mar 21;201(6):925-35.
26. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007 May;29(5):976-85.
27. Kolodsick JE, Toews GB, Jakubzick C, Hogaboam C, Moore TA, McKenzie A, et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol. 2004 Apr 1;172(7):4068-76.
28. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006 Jan;12(1):99-106.
29. Jakubzick C, Choi ES, Joshi BH, Keane MP, Kunkel SL, Puri RK, et al. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol. 2003 Sep 1;171(5):2684-93.
30. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999 Oct 21;341(17):1264-9.
31. Voltz JW, Card JW, Carey MA, Degraff LM, Ferguson CD, Flake GP, et al. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008 Jul;39(1):45-52.
32. Card JW, Voltz JW, Carey MA, Bradbury JA, Degraff LM, Lih FB, et al. Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol. 2007 Sep;37(3):300-8.
33. Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005 Mar 15;171(6):639-44.
34. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003 Nov 1;168(9):1084-90.
35. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003 Sep 1;168(5):543-8.
36. Collard HR, King TE, Jr., Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003 Sep 1;168(5):538-42.
37. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004 Aug;114(3):438-46.
38. Mehrad B, Burdick MD, Strieter RM. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1708-18.
39. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, et al. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2009 Nov;41(5):562-72.
40. Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, et al. Sirolimus-associated pulmonary toxicity. Transplantation. 2004 Apr 27;77(8):1215-20.
41. Singer SJ, Tiernan R, Sullivan EJ. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 2000 Dec 14;343(24):1815-6.